Highlights MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris Other stock markets 16:35:03 07/05/2024 BST			5-day change	1st Jan Change
14.84 ^EUR	+1.50%		+3.34%	+106.11%

05-08	CAC40: remains in green in a neglected market	CF
05-08	Medincell: positive results in schizophrenia	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CAC40: remains in green in a neglected market	05-08	CF
Medincell: positive results in schizophrenia	05-08	CF
Medincell Listing Temporarily Suspended on Euronext Paris	05-08	MT
Teva and Medincell's schizophrenia drug meets main goal of late-stage study	05-08	RE
Teva Pharmaceuticals and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-?749 as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia	05-08	CI
Medincell: share price rises following agreement with AbbVie	04-17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	04-16	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	04-16	CI
Medincell: Unitaid grant to combat malaria	04-09	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	04-09	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	03-15	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	01-09	CI
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	12-19	CI
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement	30/08/23	CI
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023	26/06/23	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	02/05/23
Teva Pharmaceuticals and MedinCell Announce FDA Approval of UZEDY (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults	29/04/23	CI
Medincell Announces Positive Results for the Saive Clinical Study in Prevention of Covid-19 Infection in A Contact-Based Population	05/01/23	CI
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2022	06/12/22	CI
MedinCell Announces the Initiation of Phase 3 Study of F14 (mdc-CWM), A Therapeutic First-In-Class That Aims to Provide Weeks of Localized Pain Relief After Total Knee Replacement	07/11/22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MedinCell S.A.

Equities

MEDCL

FR0004065605

Highlights

Filters